{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T19:23:21Z","timestamp":1749410601227},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:00:00Z","timestamp":1383091200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0077138","type":"journal-article","created":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:29:21Z","timestamp":1383179361000},"page":"e77138","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["HIV Lipodystrophy in Participants Randomised to Lopinavir\/Ritonavir (LPV\/r) +2\u20133 Nucleoside\/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV\/r + Raltegravir as Second-Line Antiretroviral Therapy"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00931463","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Allison","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W. G.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer F.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldo H.","family":"Belloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praphan","family":"Phanuphak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Ferret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Second-line study team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,10,30]]},"reference":[{"key":"ref1","first-page":"F51","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"A Carr","year":"1998"},{"key":"ref2","first-page":"F25","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome","volume":"14","author":"A Carr","year":"2000"},{"key":"ref3","first-page":"50","article-title":"Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study","volume":"31","author":"E Bernasconi","year":"2002"},{"key":"ref4","first-page":"1389","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"KA Lichtenstein","year":"2001"},{"key":"ref5","first-page":"847","article-title":"Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection","volume":"15","author":"M Van der Valk","year":"2001"},{"key":"ref6","first-page":"592","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"E Mart\u00ednez","year":"2001"},{"key":"ref7","first-page":"971","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy","volume":"17","author":"PWG Mallon","year":"2003"},{"key":"ref8","first-page":"1807","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"MP Dub\u00e9","year":"2005"},{"key":"ref9","first-page":"903","article-title":"Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study","volume":"38","author":"FJ Palella","year":"2004"},{"key":"ref10","first-page":"L5","article-title":"Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors","volume":"10","author":"H Wand","year":"2005"},{"key":"ref11","first-page":"1309","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"SA Mallal","year":"2000"},{"key":"ref12","first-page":"871","article-title":"Visceral abdominal-fat accumulation associated with use of indinavir","volume":"351","author":"KD Miller","year":"1998"},{"key":"ref13","first-page":"121","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"P Bacchetti","year":"2005"},{"key":"ref14","first-page":"39","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"JL Lennox","year":"2010"},{"key":"ref15","first-page":"255","article-title":"Examination of noninferiority, safety, and tolerability of lopinavir\/ritonavir and raltegravir compared with lopinavir\/ritonavir and tenofovir\/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results","volume":"12","author":"J Reynes","year":"2011"},{"key":"ref16","first-page":"1196","article-title":"A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir\/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE Study","volume":"28","author":"I Ofotokun","year":"2012"},{"key":"ref17","first-page":"1697","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"E Martinez","year":"2010"},{"key":"ref18","first-page":"183","article-title":"Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir","volume":"17","author":"R Minami","year":"2011"},{"key":"ref19","first-page":"475","article-title":"Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy","volume":"26","author":"A Curran","year":"2012"},{"key":"ref20","first-page":"256","article-title":"Lopinavir\/Ritonavir Combined with Raltegravir or Tenofovir\/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study","volume":"29","author":"J Reynes","year":"2013"},{"key":"ref21","first-page":"363","article-title":"High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk","volume":"31","author":"R Bruno","year":"2002"},{"key":"ref22","first-page":"1253","article-title":"Prevalence of metabolic syndrome among HIV patients","volume":"25","author":"C Gazzaruso","year":"2002"},{"key":"ref23","first-page":"426","article-title":"HIV and metabolic syndrome: a comparison with the general population","volume":"45","author":"P Bonfanti","year":"2007"},{"key":"ref24","first-page":"2445","article-title":"Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection","volume":"21","author":"H Wand","year":"2007"},{"key":"ref25","first-page":"433","article-title":"Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute\/American Heart Association Conference on scientific issues related to definition","volume":"109","author":"SM Grundy","year":"2004"},{"key":"ref26","first-page":"388","article-title":"AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases","volume":"106","author":"TA Pearson","year":"2002"},{"key":"ref27","unstructured":"Department of Health and Human Services NIH (2012) AIDSinfo website. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available: http:\/\/aidsinfo.nih.gov\/guidelines<\/ext-link>. Accessed 2013 Jun 8."},{"key":"ref28","first-page":"1841","article-title":"Pre-clinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM Study","volume":"23","author":"C Grunfeld","year":"2009"},{"key":"ref29","first-page":"1537","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D study The Data Collection on Adverse Events of Anti-HIV drugs (D: A: D) Study Group","volume":"24","author":"S Worm","year":"2010"},{"key":"ref30","first-page":"39","article-title":"Cigarette smoking and the desire to quit among individuals living with HIV","volume":"16","author":"EM Mamary","year":"2002"},{"key":"ref31","first-page":"1391","article-title":"Risk of myocardial infarction and nucleoside analogues","volume":"371","author":"JH Stein","year":"2008"},{"key":"ref32","first-page":"1252","article-title":"Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study","volume":"64","author":"M Aboud","year":"2010"},{"key":"ref33","first-page":"48","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"S Grinspoon","year":"2005"},{"key":"ref34","first-page":"1591","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial","volume":"49","author":"A Martin","year":"2009"},{"key":"ref35","first-page":"1993","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"N Friis-Moller","year":"2003"},{"key":"ref36","first-page":"726","article-title":"Raltegravir thorough QT\/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval","volume":"48","author":"M Iwamoto","year":"2008"},{"key":"ref37","first-page":"2091","article-title":"SECOND-LINE: Ritonavir-Boosted-Lopinavir with 2\u20133N(t)RTI or Raltegravir in HIV-Positive Subjects Virologically Failing First-Line NNRTI\/2N(t)RTI antiretroviral therapy","volume":"381","author":"M Boyd","year":"2013"},{"key":"ref38","first-page":"1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"PWF Wilson","year":"1998"},{"key":"ref39","first-page":"469","article-title":"Metabolic syndrome\u2013a new world-wide definition. A Consensus Statement from the International Diabetes Federation","volume":"23","author":"K Alberti","year":"2006"},{"key":"ref40","first-page":"131","article-title":"Raltegravir: The evidence of its therapeutic value in HIV-1 infection","volume":"4","author":"K Ramkumar","year":"2009"},{"key":"ref41","first-page":"S47","article-title":"Studies of Adipose Tissue Metabolism in Human Immunodeficiency Virus\u2013Associated Lipodystrophy","volume":"37","author":"DP Kotler","year":"2003"},{"key":"ref42","first-page":"48","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients","volume":"32","author":"KA Lichtenstein","year":"2003"},{"key":"ref43","first-page":"E289","article-title":"Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy","volume":"290","author":"C Hadigan","year":"2006"},{"key":"ref44","first-page":"46","article-title":"Metabolic and body composition changes after six months of highly active antiretroviral therapy in northern Indian patients","volume":"22","author":"V Gupta","year":"2011"},{"key":"ref45","first-page":"295","article-title":"Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India","volume":"44","author":"S Saghayam","year":"2007"},{"key":"ref46","first-page":"1340","article-title":"Changes in metabolic toxicity after switching from stavudine\/didanosine to tenofovir\/lamivudine\u2013a Staccato trial substudy","volume":"61","author":"J Ananworanich","year":"2008"},{"key":"ref47","first-page":"642","article-title":"Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz","volume":"194","author":"MA Boyd","year":"2006"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0077138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T17:50:46Z","timestamp":1589046646000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0077138"}},"subtitle":[],"editor":[{"given":"Javier R.","family":"Lama","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,30]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0077138","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2013,10,30]]}}}